salicylates and Bone-Neoplasms

salicylates has been researched along with Bone-Neoplasms* in 8 studies

Reviews

1 review(s) available for salicylates and Bone-Neoplasms

ArticleYear
[Osteoid osteoma and radiofrequency].
    Revue medicale suisse, 2005, Dec-21, Volume: 1, Issue:46

    Osteoid osteoma and radiofrequency Osteoid osteoma relates to a benign skeletal neoplasm, smaller than 2 cm in diameter, composed of osteoid, highly vascularized connective tissue and surrounded by a ring of bone sclerosis. Its aetiology remains unknown. It affects twice more males than female patients and occurs usually between 5 and 40 years old. Long bones and spine are the most involved areas but the whole skeleton can be involved. Clinical manifestations can include local pain (increased at night and decreased by activity) and relief with salicylates administration. CT guided radiofrequency ablation of osteoid osteoma is in comparison to surgery less invasive, time saving and economic technique with excellent long term results.

    Topics: Bone Neoplasms; Catheter Ablation; Female; Health Care Costs; Humans; Male; Osteoma, Osteoid; Pain; Salicylates; Sex Factors; Tomography, X-Ray Computed

2005

Trials

1 trial(s) available for salicylates and Bone-Neoplasms

ArticleYear
The efficacy of choline magnesium trisalicylate (CMT) in the management of metastatic bone pain: a pilot study.
    Palliative medicine, 1994, Volume: 8, Issue:2

    Twenty-six patients with painful, bony metastases were recruited into a randomized, double-blind, single dose, two-treatment, three-part crossover study of choline magnesium trisalicylate (CMT) and placebo. Assessments were made prior to and at one, two, three and four hours after dosing. Bone pain caused by metastatic cancer was significantly relieved one hour after the administration of 1500 mg CMT (p = 0.04). At all four time points the pain was less than baseline with CMT and at three time points greater than baseline with placebo but these results did not reach statistical significance. The summed pain intensity difference for patients was greater with CMT than with placebo, but this also did not reach significance. The incidence of volunteered side-effects was similar for both treatments. The results suggest that a nonacetylating, nonsteroidal anti-inflammatory drug may have a role complementary to that of an opioid in the management of metastatic bone pain.

    Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Bone Neoplasms; Choline; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Pain; Pain Measurement; Palliative Care; Salicylates

1994

Other Studies

6 other study(ies) available for salicylates and Bone-Neoplasms

ArticleYear
The Osteosarcoma Stem Cell Activity of a Gallium(III)-Phenanthroline Complex Appended to Salicylate.
    Chembiochem : a European journal of chemical biology, 2022, 12-16, Volume: 23, Issue:24

    We report the synthesis, characterisation, and anti-osteosarcoma properties of a gallium(III) complex (1) comprising of two 1,10-phenanthroline ligands and salicylate, a non-steroidal anti-inflammatory drug. The gallium(III) complex 1 displays micromolar potency towards bulk osteosarcoma cells and osteosarcoma stem cells (OSCs). Notably, the gallium(III) complex 1 exhibits significantly higher toxicity towards OSCs grown in monolayer and three-dimensional cultures than cisplatin, a frontline anti-osteosarcoma drug. Nuclei isolation and immunoblotting studies show that the gallium(III) complex 1 enters osteosarcoma cell nuclei and induces DNA damage. Flow cytometry and cytotoxicity studies (in the presence of prostaglandin E2) indicate that the gallium(III) complex 1 downregulates cyclooxygenase-2 (COX-2) expression and kills osteosarcoma cells in a COX-2-dependent manner. Further, the mode of osteosarcoma cell death evoked by the gallium(III) complex 1 is characterised as caspase-dependent apoptosis.

    Topics: Antineoplastic Agents; Apoptosis; Bone Neoplasms; Cell Line, Tumor; Cyclooxygenase 2; Gallium; Humans; Osteosarcoma; Phenanthrolines; Salicylates; Stem Cells

2022
Osteoid osteoma of the great toe: dermatological signs as a disease spy.
    International journal of dermatology, 2020, Volume: 59, Issue:6

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Bone Neoplasms; Diagnosis, Differential; Female; Foot Dermatoses; Humans; Nail Diseases; Nails; Onychomycosis; Osteoma, Osteoid; Salicylates; Toes; Young Adult

2020
Radiology case of the month. Painful left hip relieved by salicylates. Osteoid osteoma.
    The Journal of the Louisiana State Medical Society : official organ of the Louisiana State Medical Society, 1998, Volume: 150, Issue:5

    Topics: Adult; Bone Neoplasms; Hip; Humans; Male; Osteoma, Osteoid; Pain; Pain Measurement; Salicylates; Tomography, X-Ray Computed

1998
Drug treatments for relief of pain due to bone metastases.
    Journal of the Royal Society of Medicine, 1985, Volume: 78 Suppl 9

    Topics: Acetaminophen; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bone Neoplasms; Delayed-Action Preparations; Dextropropoxyphene; Drug Therapy, Combination; Female; Humans; Morphine; Palliative Care; Salicylates

1985
Administration of prostaglandins A and E and antiinflammatory drugs to patients with cancer.
    Advances in prostaglandin, thromboxane, and leukotriene research, 1983, Volume: 12

    Topics: Bone Neoplasms; Breast Neoplasms; Female; Humans; Leukemia, Myeloid, Acute; Neoplasms; Prostaglandins A; Prostaglandins E; Salicylates

1983
[Differential diagnostic problems of osteoid osteoma in childhood].
    Archiv fur orthopadische und Unfall-Chirurgie, 1972, Volume: 73, Issue:4

    Topics: Adolescent; Bone Neoplasms; Child; Diagnosis, Differential; Female; Femoral Neoplasms; Humans; Male; Osteoma, Osteoid; Pain; Radiography; Salicylates; Tibia

1972